Celebrex 1999 Study Showing Cardiovascular Risk Was Disclosed, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The study was presented at a scientific meeting in 2000 and submitted to FDA in 2001, Pfizer says. The cardiovascular events seen in the Alzheimer's study, highlighted in a recent Public Citizen letter to FDA, do not indicate a danger from Celebrex because of the underlying cardiovascular risk profile of the celecoxib arm, Pfizer says.